Department of Neurology, Afyonkarahisar University of Health Sciences, Afyonkarahisar, Turkey.
Cerrahpasa Faculty of Medicine, Department of Neurology and Clinical Neurophysiology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Int J Neurosci. 2023 Jan;133(1):86-88. doi: 10.1080/00207454.2021.1886097. Epub 2021 Feb 12.
After the first COVID-19 case, reported neurological complications are increasing day by day.
In this paper, we present a benign-course Guillain-Barré syndrome (GBS) emerging 2 weeks after COVID-19 infection in a 35-years-old male.
Cough and fever were started 18 days ago and his PCR test was resulted positive for COVID-19 infection. After treatment and quarantine were completed, he developed sudden leg weakness following autonomic features. Cerebrospinal fluid was suggestive for GBS despite the electrodiagnostic test was not helpful because it was done in the first days. He recovered without needing any immunotherapy.
Our case suggested that COVID-19 can cause atypical benign GBS forms in addition to well-known variants. Comprehensive studies are needed to describe the unknowns and determine the exact prevalence of GBS after COVID-19 infection, including mild cases that did not require hospital admission.
首例 COVID-19 病例报告以来，神经系统并发症日益增多。
本文报道了 1 例 35 岁男性 COVID-19 感染后 2 周出现良性病程格林-巴利综合征（GBS）。
18 天前出现咳嗽和发热，PCR 检测 COVID-19 感染阳性。完成治疗和隔离后，他出现了自主神经特征的突发性下肢无力。尽管电诊断测试没有帮助，因为它是在最初几天进行的，但脑脊液提示为 GBS。他未经免疫治疗即康复。
我们的病例表明，COVID-19 除了已知变异外，还可能引起不典型良性 GBS 形式。需要进行全面研究，以描述未知情况并确定 COVID-19 感染后 GBS 的确切流行率，包括无需住院的轻症病例。
